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Background - The frequency of kidney transplantation (KT) is increasing. Blood 
transfusion plays an important role in the success of KT. Therapeutic plasma exchange 
(TPE) is also used for desensitisation in ABO-incompatible KT and treatment of 
antibody-mediated rejection.
Materials and methods - We analysed red blood cell (RBC), platelet, and fresh 
frozen plasma (FFP) usage and the number of TPE procedures performed during the 
hospitalisation of KT patients from 2002 to 2017 using the Korean National Health 
Insurance Service-National Health Information Database.
Results - A total of 18,331 KT patients were included in this study. The number of 
transfused RBCs continued to increase from 4,806 units in 2002-2005 to 12,390 units 
in 2014-2017. However, the average number of RBCs transfused per patient decreased 
from 2.17 to 1.79 units. Estimated platelet usage increased from 4,259 units in 2002-
2005 to 11,519 units in 2014-2017, and the proportion of filtered platelets increased 
from 72.6% to 83.4% during the same period. There was a huge increase in the total 
number of FFP units used, from 2,255 units in 2002-2005 to 51,531 units in 2014-2017. 
The number of TPE procedures performed also increased from 296 to 6,479 during 
the same period. Patients with acute rejection accounted for 8.8% of all KT patients, 
and more RBC and FFP were used for these patients and a greater number of TPE 
procedures were performed compared to those who did not experience rejection.
Discussion - Blood usage and TPE have increased steadily with the increasing 
numbers of KTs. Therefore, continuous efforts are needed to ensure appropriate 
perioperative blood preparation and usage for KT patients.
Keywords: kidney transplantation, therapeutic plasma exchange, blood transfusion, 
fresh frozen plasma.
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INTRODUCTION
As the incidence of chronic kidney diseases increases, kidney transplantation (KT) is also 
showing an increasing trend1. Currently, more than 20,000 KTs are performed per year in 
the United States2. In South Korea, the number of KTs also continues to increase, and there 
are currently over 2,000 KTs performed per year3. Blood transfusion plays an important 
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have undergone haematopoietic stem cell or solid organ 
transplantations14.
Meanwhile, ABO incompatibility (ABOi) between recipients 
and donors is an important immunological barrier to KT15 
since it is often associated with early graft loss due to 
antibody-mediated allograft rejection. However, ABOi KT 
has been made possible in different countries around the 
world due to the development of ABOi KT protocols16,17. In 
these protocols, therapeutic plasma exchange (TPE) plays 
a role in reducing the titre of isoagglutinins to a donor’s 
ABO antigens and in maintaining a low isoagglutinin titre 
for a certain period of time after surgery18,19. During TPE 
procedures, the recipient’s plasma is replaced by albumin 
solution and/or fresh frozen plasma (FFP). In addition, TPE 
is used as a tool for treating antibody-mediated rejection 
in transplant recipients. Consequently, the role of blood 
banks in hospitals that implement organ transplants is 
becoming more important through perioperative blood 
management and TPE in KT.
In this study, we analysed the number of RBC, platelet, 
and FFP units used during the hospitalisation of 
patients who underwent KT using the Korean National 
Health Insurance Service-National Health Information 
Database (NHIS-NHID) from 2002 to 2017. We also 
investigated the number of perioperative TPE procedures 
performed for the KT patients. We aimed to examine 
the status of blood usage and TPE in KTs and to provide 
available data on the amount of RBC, platelet, and FFP 




All individuals in South Korea have been obliged to join the 
Korean NHIS since the service started in 1989. The NHIS 
controls all medical costs among individuals, healthcare 
providers, and the government. Therefore, medical data 
including personal information, diagnosis, medical 
treatment, and demographics of patients have been 
centralised in the NHID. All claims are managed through 
the use of Electronic Data Interchange (EDI) codes. In 
addition, the NHIS-NHID includes the diagnosis of 
patients using the Korean Classification of Diseases (KCD) 
codes, which is the Korean version of the International 
Classification of Diseases (ICD).
end-stage renal disease (ESRD) are anaemic4. Red blood 
cell (RBC) transfusions correct anaemia for patients 
awaiting KT and supplement blood loss during surgery. 
However, blood transfusions are associated with serious 
complications such as transfusion-related acute lung 
injury, transfusion-associated circulatory overload, and 
transmission of viral pathogens5,6. Therefore, when blood 
is transfused into a KT patient, we should consider the 
benefits of transfusion vs the risks involved.
Meanwhile, alloimmunisation to the human leukocyte 
antigen (HLA) is well recognised as causing the common 
side effects of blood transfusions7. HLA antigens are 
expressed on both platelets and leukocytes. Although 
RBCs do not present HLA antigens, RBC preparations 
usually contain a large number of leukocytes, which could 
lead to HLA alloimmunisation8. Consequently, RBC and 
platelet preparations usually involve white blood cell 
(WBC) removal before transfusion into transplantation 
recipients. When lymphocytes are transfused to patients, 
especially to those with poor immune function such as those 
undergoing solid organ or bone marrow transplantations 
and those receiving radiation or chemotherapy, 
transfusion-associated graft-vs-host disease (TA-GvHD) 
may be induced. This occurs when the lymphocytes of 
blood donors proliferate in the recipient and attack tissues 
such as epithelial cells. TA-GvHD causes symptoms such 
as skin rash, fever, decreased liver function, jaundice, 
diarrhoea, and pancytopenia. Moreover, TA-GvHD is 
known to be associated with high mortality (approx. 90-
100%9) and thus must be prevented. However, it is still 
not clear whether a blood product needs to be irradiated 
in the case of transplantation recipients. Solid organ 
transplantation is not considered to be a high risk factor 
for TA-GvHD in the British guideline on transfusion10, 
while another guideline identifies immunocompromised 
recipients of organ transplantation as candidates for 
blood irradiation11. TA-GvHDs had been reported in a 
few cases after solid organ transplantation12,13, and using 
a WBC removal filter to produce leukoreduced blood 
products is not sufficient to prevent TA-GvHD. Thus, blood 
products could, in addition, be irradiated in the case of 
transplantation recipients before being transfused. In the 
South Korean guideline on blood transfusion practices, it 
is intended that irradiation of blood products be adopted 
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Study subjects
In the NHIS-NHID (2002-2017), data related to health 
insurance claims for a total of 20,750 patients during 
hospitalisations for KTs were analysed. The data from 
21,191 reimbursed KT claims for the 20,750 patients were 
reviewed, and only the time prior to repeated surgery (if 
the same patient had undergone two or more KTs) was 
included in the analysis. Among them, 2,219 subjects 
who were considered as having received repeated KTs 
(with a history of previous KT and/or with continuous 
immunosuppressive medication prescribed prior to KT) 
and 200 with unclear medical histories were also excluded 
from the data analysis. This means that the study was 
conducted on a total of 18,331 patients who underwent KT 
for the first time during this 16-year period.
Variable definitions
We investigated the sex, age, hospital type, and 
occurrence of acute allograft rejection (AR) in a total of 
18,331 KT patients. In addition, we analysed the number 
of TPE procedures performed, as well as the number of 
RBC, platelet, FFP, and albumin units utilised in the same 
subjects. One unit of packed RBC contains approximately 
200 or 250 mL of blood products separated respectively 
from 320 or 400 mL of a donor’s whole blood. In the 
same manner, one unit of random donor platelets (RDP) 
containing approximately 0.5-0.7x1011 platelets consists 
of approximately 40-50 mL volume separated from 320 
or 400 mL of whole blood. In addition, one unit of single 
donor platelets (SDP) is usually processed in 250 mL 
volume, which contains 3.0-4.0x1011 platelets. One FFP 
unit is usually manufactured in 160-180 mL volume. 
Meanwhile, bottles of 5% albumin solution in 250 mL 
or 20% albumin solution in 100 mL volume were used 
in the KT patients. Patients were classified into 4 age 
groups: <20, 20-39, 40-59, and ≥60 years old). Hospital 
types were classified into two separate groups: general 
hospitals (defined as having at least 100 beds) and tertiary 
hospitals (designated by the Korean Ministry of Health 
and Welfare as certain general hospitals that specialise 
in more complex medical treatments for severe diseases). 
Currently, there are 42 tertiary hospitals in South Korea. 
In order to analyse blood usage and the number of TPE 
procedures performed according to time period, a total of 
16 years (2002-2017; the time period covered by the study) 
were divided into four groups of four years each. Since it 
is difficult to specify the exact time of kidney allograft 
rejection due to the characteristics of the National Health 
Insurance claim data, AR was defined as any case where 
the diagnosis of kidney allograft rejection by ICD-10 
codes T86 and/or T86.1 was recorded during the KT 
surgery-related hospitalisation period.
Statistical analysis
The Mann-Whitney U and Wilcoxon signed-rank tests were 
used to compare continuous variables between subject 
groups, and the χ2 test was used to compare categorical 
variables. All statistical analyses were performed by SAS 
7.15 (SAS Institute Inc., Cary, NC, USA) and RStudio 
v1.1.463 (RStudio Inc., Boston, MA, USA). p-values<0.05 
were considered statistically significant.
Study approval
This study protocol was reviewed and approved by 
the Institutional Review Board of the National Health 
Insurance Service Ilsan Hospital (Institutional Review 
Board approval no. NHIMC 2019-01-001). This study used 
the NHIS-NHID (2002-2017), which was approved by the 
NHIS. The administration no. of the National Health 
Insurance Sharing Service was REQ0000029922.
RESULTS
Study subjects
Of a total of 18,331 KT recipients in our study, 10,934 (59.6%) 
were male and 7,397 (40.4%) were female. The number of 
KTs continued to increase from 509 in 2002 to 1,865 in 2017 
(Figure 1). In particular, the number of patients increased 
to figures over those of the previous year in 2006, 2011, 
and 2016. At the time of KT, the most common age group 
was those aged 50-59 years (5,738; 31.3%), followed by those 
aged 40-49 (4,917; 26.8%) and 30-39 years (3,298; 18.0%). 
Among the 18,331 cases, 15,662 (85.4%) KTs were performed 
in tertiary hospitals and 2,669 (14.6%) were performed in 
general hospitals.
RBC preparation usage
Regardless of the type of RBC preparation, the number of 
transfused RBC units continued to increase from 4,806 
units in 2002-2005 to 12,390 units in 2014-2017 (Table I). 
However, the average number of units transfused per KT 
patient decreased from 2.17 to 1.79, respectively, in the 
same two study periods.
In filtered RBC units, the total number of units transfused, 
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filtered RBC units among all RBC preparations continued 
to increase during the study period. The percentage 
of filtered RBC units increased steadily from 62.8% in 
2002-2005 to 81.8% in 2014-2017. However, the average 
number of filtered RBC units per transfused patient 
was maintained at around 4 units, except in the period 
2002-2005.
In the case of packed RBCs, excluding filtered RBC and 
washed RBC, the total number of RBC units transfused, 
number of transfused patients, and the proportion of RBC 
units continued to decrease during the study period. 
In addition, the number of patients who were transfused 
with any type of RBCs increased from 1,097 in 
2002-2005 to 3,179 in 2014-2017, but the percentage of 
patients transfused with any type of RBCs among all KT 
patients remained constant at approximately 50% during 
the period 2002-2013, to then decrease to 45.9% during the 
period 2014-2017.
Platelet preparation usage
Perioperative platelet usage is summarised in Table II. A 
single unit of RDP contains approximately 0.5-0.7x1011 
platelets, and one SDP unit contains approximately 
3.0-4.0x1011 platelets. In this study, we counted 6 RDP 
units as one SDP. In the case of RDP, an average of 
35.3 units were transfused to 1.5% of all KT patients in 
2002-2005, while an average of 21.5 units to 1.3% of 
patients in 2014-2017 and an average of 23.5 units to 1.6% 
of KT patients over the entire study period were used.
Table I - Perioperative red blood cell (RBC) unit usage in kidney transplantation by period
RBC type
Year





N. of units transfused 1,717 1,740 2,048 1,248 6,753
N. of transfused patients 543 528 622 465 2,158
Mean n. of units per transfused 
patient 3.2 3.3 3.3 2.7 3.1
% transfused patients 24.5 14.1 11.4 6.7 11.8
Filtered RBC
N. of units transfused 3,018 5,859 8,918 10,132 27,927
N. of transfused patients 647 1,449 2,203 2,616 6,915
Mean n. of units per transfused 
patient 4.7 4.0 4.0 3.9 4.0
% transfused patients 29.2 38.8 40.4 37.8 37.7
Washed RBC
N. of units transfused 71 246 1,309 1,010 2,636
N. of transfused patients 30 59 241 296 626
Mean n. of units per transfused 
patient 2.4 4.2 5.4 3.4 4.2
% transfused patients 1.4 1.6 4.4 4.3 3.4
Total n. of units transfused 4,806 7,845 12,275 12,390 37,316
% filtered RBC 62.8 74.7 72.7 81.8 74.8
N. of patients transfused with any type of RBCs 1,097 1,939 2,893 3,179 9,108
% patients transfused with any type of RBCs 49.4 51.9 53.0 45.9 49.7
Transfusion-free patientsa 988 1,647 2,180 2,959 7,774
% transfusion-free patients 44.5 44.1 40.0 42.8 42.4
Mean n. of units transfused per KT patient 2.2 2.1 2.3 1.8 2.0
Total n. of KT patients 2,219 3,738 5,454 6,920 18,331
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In the case of filtered RDP, an average of 67.5 units were 
used for 1.8% of all KT patients in 2002-2005; however, 
during 2014-2017, an average of 19.4 units were used 
for 3.2% of KT patients. The proportion of patients who 
received filtered RDP slightly increased, but the average 
units transfused per patient decreased over time. During 
the study period, the average filtered RDP used per KT 
patient was 26.1 units, with 15,649 units transfused to 3.3% 
of all KT patients.
Regarding SDP, an average of 4.8 units were used for 0.7% 
of all KT patients in 2002-2005, but an average of 3.9 units 
were used for 3.3% of KT patients in 2014-2017. Overall, 
an average of 3.9 SDP units were transfused to 2.2% of KT 
patients over the entire period with an increasing trend in 
the proportion of patients with SDP transfusions.
An estimated 32,044 platelet units were used in all KT 
patients over the 16-year period, with an average use per 
KT patient of 1.7 units, when SDP was estimated to be 
equivalent to 6 RDPs. The estimated percentage of filtered 
platelets increased from 72.6% in 2002-2005 to 83.4% in 
2014-2017.
Table II - Perioperative platelet unit usage in kidney transplantation by period
PLT type
Year
2002-2005 2006-2009 2010-2013 2014-2017 Total
RDP (A)
N. of units transfused 1,166 1,276 2,479 1,910 6,831
N. of transfused patients 33 58 111 89 291
Mean n. of units per transfused patient 35.3 22.0 22.3 21.5 23.5
% transfused patients 1.5 1.6 2.0 1.3 1.6
Filtered RDP
(B)
N. of units transfused 2,631 2,787 5,944 4,287 15,649
N. of transfused patients 39 121 218 221 599
Mean n. of units per transfused patient 67.5 23.0 27.3 19.4 26.1
% transfused patients 1.8 3.2 4.0 3.2 3.3
SDPᵃ 
(C)
N. of units transfused 77 99 531 887 1,594
N. of transfused patients 16 36 130 230 412
Mean n. of units per transfused patient 4.8 2.8 4.1 3.9 3.9
% transfused patients 0.7 1.0 2.4 3.3 2.2
Total n. of units transfused (D),  D = A+ B+ C × 6 4,259 4,657 11,609 11,519 32,044
% filtered platelets,  (B + C × 6) ÷ D 72.6 72.6 78.6 83.4 78.7
% SDP,  C × 6 ÷ D 10.8 12.8 27.4 46.2 29.8
N. of patients transfused with any types of platelets 73 181 371 451 1,706
% patients transfused with any types of platelets 3.3 4.8 6.8 6.5 5.9
Transfusion-free patientsᵇ 988 1,647 2,180 2,959 7,774
% transfusion-free patients 44.5 44.1 40.0 42.8 42.4
Mean n. of units transfused per KT patient 1.9 1.2 2.1 1.7 1.7
Total n. of patients 2,219 3,738 5,454 6,920 18,331
aPlatelet equivalents: 1 SDP = 6 RDP. bPatients without any transfusion including RBC, platelets, and fresh frozen plasma.
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FFP and albumin usage and TPE procedures
The perioperative use of FFP and albumin and of TPE 
procedures for KTs in each period is summarised in Table 
III and Figure 1. In the case of FFP, an average of 8.9 units 
were transfused to 11.4% of all KT patients in 2002-2005, 
while an average of 32.8 units were transfused to 22.7% 
of patients during 2014-2017, resulting in a continuous 
increase in usage and in the percentage of patients with 
FFP transfusion. In addition, the percentage of FFP 
usage in the patients who underwent TPE among the FFP 
usage in all KT patients also continuously increased from 
29.6% in 2002-2005 to 93.6% in 2014-2017. Overall, 87.7% 
of all FFP units used during the entire study period were 
transfused into the patients who underwent TPE.
The percentage of patients who were infused with albumin 
varied between 42.9% and 57.4% each year, but the total 
annual usage increased from 1,063 in 2002 to 10,697 in 
2017 due to the increase in the number of KTs. In addition, 
64.9% of all albumin solution used throughout the entire study 
period was infused into the patients who underwent TPE.
Regarding perioperative TPE, the percentage of patients 
who underwent plasma exchange increased from 6.3% in 
2002-2005 to 20.1% in 2014-2017. The number of patients 
who underwent TPE and the total number of annual 
plasma exchange procedures also saw a continuous 
increase during the period studied.
Blood use and TPE according to AR
Table IV summarises the number of blood preparations, 
albumin usage, and the number of TPE procedures 
performed according to the occurrence of AR during 
the study periods. The average number of RBC and FFP 
units used per transfused patient, percent of RBC- and 
Table III - Perioperative fresh frozen plasma and albumin usage and therapeutic plasma exchange in kidney transplantation by period
Blood products/TPE Parameter
Years
2002-2005 2006-2009 2010-2013 2014-2017 Total
FFP
All KT patients
N. of units transfused 2,255 7,562 40,487 51,531 101,835
N. of transfused patients 252 518 1,216 1,573 3,559
Mean n. of units per transfused patient 8.9 14.6 33.3 32.8 28.6
% transfused patients 11.4 13.9 22.3 22.7 19.4
Patients 
undergone TPE
N. of units transfused 668 4,030 36,388 48,241 89,323
Mean n. of units per transfused patient 4.8 11.8 36.4 34.6 31.1
% use in TPE patients among all KT 
patients 29.6 53.3 89.9 93.6 87.7
Albumin
All KT patients
Total usage (bottle) 3,026 7,509 14,651 29,307 54,493
N. of patients infused 1,094 1,866 2,628 3,338 8,926
Mean usage per patient (bottle) 2.8 4.0 5.6 8.8 6.1
% patients infused 49.3 49.9 48.2 48.2 48.7
Patients 
undergone TPE
Total usage (bottle) 594 3,654 9,175 21,964 35,387
Mean usage per patient (bottle) 4.3 10.7 9.2 15.8 12.3
% use in TPE patients among all KT 
patients 19.6 48.7 62.6 74.9 64.9
TPE
N. of TPE performed 296 901 3,840 6,479 11,516
N. of patients undergone TPE 139 341 1,000 1,393 2,873
Mean n. per patient undergone TPE 2.1 2.6 3.8 4.7 4.0
% patients undergone TPE 6.3 9.1 18.3 20.1 15.7
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FFP-transfused patients, average number of TPE procedures 
performed, and the proportion of patients who underwent 
TPE were higher in patients with AR than without AR.
In the case of RBC preparations, an average of 3.5 units per 
patient were transfused in 48.3% of KT patients without AR, 
compared with an average of 6.7 units per patient that were 
transfused in 61.5% of KT patients with AR. In addition, 
an average of 24.4 FFP units per patient were transfused 
in 17.8% of KT patients without AR, while an average of 
50.4 FFP units per patient were used in 35.9% of KT patients 
with AR. Finally, an average 4.8 TPE procedures were 
performed in 30.3% of all KT patients with AR, compared 
with an average 3.8 in 14.3% of KT patients without AR. 
Demographics of KT patients with or without AR
Table V compares the groups of patients with or without 
AR. A total of 1,605 (8.8%) patients experienced AR. The 
proportion of male patients was significantly higher in 
the group without AR. There was no difference in mean 
age between the two groups, but the proportions of each 
age group in the two groups differed. The AR group had a 
higher proportion of KT patients aged 20-59 years old. 
Meanwhile, the incidence of AR was 16.6% among 2,219 KT 
recipients in 2002-2005, whereas the incidence in 2014-2017 
was 5.8% among 6,920 KT patients, showing a decreasing 
trend of AR incidence throughout the study period. The 
length of hospital stay and medical costs were higher in 
the AR group. Furthermore, the use of albumin, FFP, and 
RBC preparations, and the number of TPE procedures 
performed were also significantly higher in the AR group.
DISCUSSION
Kidney transplantation is the ideal treatment for patients 
with ESRD20. In the case of deceased donor transplantation, 
in which the ABO blood group and HLA antigen types of 
the donor and recipient are all identical, the organs will be 
preferentially transplanted. As of 2016, KTs from deceased 
Figure 1 - Changes in the total number of patients (*), and the numbers of patients who underwent perioperative 
therapeutic plasma exchanges (TPE) (■), perioperative TPE performed (●), fresh frozen plasma (FFP) units transfused 
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donors has continued to increase, accounting for 47.4% of 
all KT cases in South Korea21, but an even higher number 
of KT recipients have received kidney allografts from living 
donors. KTs from living donors may be contraindicated 
owing to the increased possibility of AR if the ABO blood 
group is incompatible between the donor and recipient 
or if the patient has antibodies against the donor HLAs. 
However, a variety of desensitisation methods have 
recently been used to remove antibodies against ABO 
antigens or HLAs22,23. These methods include antibody 
removal using TPE or immunoadsorption, and/or immune 
system regulation using agents such as intravenous 
immunoglobulins, rituximab (monoclonal anti-CD20 
antibody), or bortezomib (proteasome inhibitor).
Since ABOi KT was first used in South Korea in 2007, the 
proportion of ABOi KTs has increased and accounted for 
26.3% of KTs from living donors in 20183. In this study, 
we analysed the trends in the number of TPE procedures 
performed and the use of albumin and FFP related to KT. 
The number of KTs performed each year had increased 
steadily from 509 cases in 2002 to 1,865 cases in 2017 
(Figure 1). Meanwhile, the number of TPE procedures 
performed had increased slightly from 85 cases in 2002 to 
272 cases in 2009, but increased sharply from 587 cases in 
2010 to 1,877 cases in 2017. Parameters regarding the use 
of FFP, including the number of transfused patients and 
proportion of transfused patients among KT recipients, 
had increased during the study periods (Table III). On the 
other hand, the total number of transfused FFP units had 
increased rapidly from 2010, as did TPE, but no further 





(n. of patients, %) Parameter
Years





N. of units transfused 3,050 6,002 9,111 9,937 28,100
N. of transfused patients 978 1,734 2,545 2,829 8,086
Mean n. of units per transfused patient 3.1 3.5 3.6 3.5 3.5
% transfused patients 52.8 52.0 50.7 43.4 48.3
Yes
(1,605; 8.8%)
N. of units transfused 1,685 1,597 1,855 1,443 6,580
N. of transfused patients 212 243 280 252 987
Mean n. of units per transfused patient 7.9 6.6 6.6 5.7 6.7




N. of units transfused 900 4,260 29,373 38,285 72,818
N. of transfused patients 185 391 1,028 1,379 2,983
Mean n. of units per transfused patient 4.9 10.9 28.6 27.8 24.4
% transfused patients 10.0 11.7 20.5 21.2 17.8
Yes
(1,605; 8.8%)
N. of units transfused 1,355 3,302 11,114 13,246 29,017
N. of transfused patients 67 127 188 194 576
Mean n. of units per transfused patient 20.2 26.0 59.1 68.3 50.4




N. of TPE performed 171 552 3,048 5,411 9,182
N. of patients undergone TPE 32 109 790 1,455 2,386
Mean n. per patient undergone TPE 5.3 5.1 3.9 3.7 3.8
% patients undergone TPE 1.7 3.3 15.7 22.3 14.3
Yes
(1,605; 8.8%)
N. of TPE performed 125 349 792 1,068 2,334
N. of patients undergone TPE 25 61 173 228 487
Mean n. per patient undergone TPE 5.0 5.7 4.6 4.7 4.8
% patients undergone TPE 6.8 15.1 40.0 56.9 30.3
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increases were seen after 2012. Regarding albumin, 
the total usage showed a gradual increase, but this rose 
rapidly after 2015 (Figure 1). This could have been caused 
by a recent increase in the use of albumin instead of FFP 
as the replacement f luid for TPE.
Compared to the increase in FFP use, the overall use of RBC 
preparations showed a constant increase from 4,806 units 
in 2002-2005 to 12,390 units in 2014-2017, but the mean 
number of RBC units transfused per KT patient decreased 
from 2.17 to 1.79 units for the same period of time, with 
2.04 units per KT patient being used throughout the 
entire study period (Table I). In addition, the estimated 
usage of total platelet preparations regardless of platelet 
type continued to increase from 4,336 units in 2002-2005 
to 12,406 units in 2014-2017, but the average number of 
units transfused per KT patient decreased from 1.92 to 
1.66 units during the same period of time. When RBC 
and platelet preparations are transfused before and 
after organ transplantation, leukocyte filtration and 
irradiation of blood products may be required to prevent 
HLA alloimmunisation and platelet refractoriness caused 
by WBC in those preparations, and to prevent TA-GvHD 
and transmission of viruses such as cytomegalovirus 
and human T-cell leukemia virus24. In this study, the 
number of filtered RBC units used and number of patients 
transfused with filtered RBCs continuously increased 
over the study period, but the average number of units 
per transfused patient has remained constant at around 4 
units since 2006 (Table I). The percentage of filtered RBCs 
among total RBC preparations had been on a steady rise 
from 62.8% in 2002-2005 to 81.8% in 2014-2017. These 
results would imply that clinical practices regarding blood 
Table V - Demographics of kidney transplantation patients with or without acute kidney
Characteristics No AR (n=16,726) AR (n=1,605) p-value
N. of male (%) 10,080 (60.3) 854 (53.2) <0.0001
Age (years)ᵃ 46.8 ± 12.4 46.3 ± 12.0 0.0934
Age group, n. (%) 0.0293
<20 413 (2.5) 30 (1.9)
20-39 4,129 (24.7) 419 (26.1)
40-59 9,701 (58.0) 954 (59.4)
≥60 2,483 (14.8) 202 (12.6)
Hospital type, n. (%) 0.0513
Tertiary 14,317 (85.6) 1,345 (83.8)
General 2,409 (14.4) 260 (16.2)
Periods <0.0001
2002-2005 1,851 (11.1) 368 (22.9)
2006-2009 3,335 (19.9) 403 (25.1)
2010-2013 5,021 (30.0) 433 (27.0)
2014-2017 6,519 (39.0) 401 (25.0)
Length of hospital stay (days)ᵇ 25 (19-33) 30 (22-43) <0.0001
Medical costs (1,000 KRW)b,c 16,683 (13,365-20,803) 18,954 (13,086-29,070) <0.0001
TPE
N. of patients (%) 2,386 (14.3) 487 (30.3) <0.0001
N. of TPE performedb,d 3 (2-5) 4 (2-6) <0.0001
Albumin infused (bottle)ᵇ 3 (1-3) 3 (1-9) <0.0001
FFP transfused (unit)ᵇ 11 (3-30) 20 (5-68) <0.0001
Filtered RBC used (unit)ᵇ 2 (2-4) 4 (2-7) <0.0001
Packed RBC used (unit)ᵇ 2 (1-3) 3 (2-6) <0.0001
ᵃShown as ‘mean ± standard deviation’. ᵇShown as ‘median (1st to 3rd quartiles)’. ᶜ1 US Dollar = 1167.1 KRW (South Korean Won), 03/01/2020. dN. of TPE 
procedures performed per patient who underwent TPE. 
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transfusions for KT recipients had been heterogenous 
across South Korea. Similarly, the percentage of filtered 
platelets had also steadily increased from 72.6% in 
2002-2005 to 83.4% in 2014-2017 (Table II). This is thought 
to have resulted not only from the increased use of filtered 
platelets, but also the increased use of SDPs (from 10.8% in 
2002-2005 to 46.2% in 2014-2017).
Meanwhile, the differences between the characteristics 
of patients with or without AR are summarised in Table V. 
The proportion of males was significantly lower in the AR 
group. Alloimmunisation and rejection are usually more 
frequent in females, but the reported effects of sex in 
developing kidney allograft rejection were inconsistent in 
several previous studies25-27. In our results, the incidence 
of AR showed a decreasing trend over time. Induction of 
immune suppression by agents including antithymocyte 
globulin has been known to be effective in the prevention 
of AR28,29. Use of new immunosuppressive drugs such 
as sirolimus and mycophenolate mofetil have also been 
shown to reduce the incidence of AR in KT patients30,31. The 
growing clinical experience, along with improvements in 
surgical techniques and patient management, seem to 
have contributed to the decrease in AR.
In the AR group of our data, hospital stay was longer and 
medical costs higher compared to those among patients 
without AR. The number of TPE procedures performed, as 
well as the use of albumin, FFP, and RBC were also higher 
in the AR group. Greater use of blood products and TPE 
in our data would be considered to be one of the reasons 
for the increase in medical costs for hospitalisation in the 
AR group. One previous study reported that development 
of AR led to increased medical costs, accounting for 
2.3-3.8% of total incurred costs over one year after KT32. 
In this study, differences were seen in the consumption of 
medical resources including blood products according to 
the occurrence of AR; therefore, the clinical condition of 
KT recipients should be considered when preparing blood 
products in the blood banks of institutions performing KT.
This study analysed a 16-year period using the Korean 
NHIS-NHID and investigated the use of blood preparations 
for a total number of 18,331 patients who underwent KT for 
the first time in South Korea. Due to the limitations of 
the data related to health insurance claims, we were not 
able to distinguish between pre- and post-operative blood 
transfusions, and we were also unable to obtain detailed 
clinical information about KT patients, such as the exact 
timing of the AR occurrence, whether the KT recipient and 
donor were ABOi, or whether the donor type was "living" 
or "deceased". Despite these shortcomings, our data have 
identified trends in blood use in KTs, since it covered most 
of the blood preparations used and plasma exchanges 
performed for KT patients during a 16-year period in 
South Korea.
CONCLUSIONS
In this study, we confirmed a continued increase in 
blood usage as the number of KTs increased. FFP and 
albumin usage, as well as the number of TPE procedures 
performed, also increased significantly over time. 
Although there was no increase in the average number 
of units transfused per KT patient in the case of RBC and 
platelet preparations, total blood usage increased steadily 
as the number of KTs increased. There is a growing need 
for appropriate use of blood resources due to ageing 
populations worldwide. Therefore, blood banks are 
assuming an ever more important role in successful KTs. 
In conclusion, continuous efforts are needed to ensure 
proper perioperative preparation and usage of blood for 
KT patients.
ACKNOWLEDGEMENTS
This work was supported by the National Health Insurance 
Ilsan Hospital grant (2019-20-002). This study used 
NHIS-NHID data (REQ0000029922), made by National 
Health Insurance Service. This study was approved by the 
Institutional Review Board of National Health Insurance 
Service Ilsan Hospital (Institutional review board No: 
NHIMC 2019-01-001).
FUNDING AND RESOURCES
This work was supported by the National Health Insurance 
Ilsan Hospital grant (2019-20-002). This study used NHIS-
NHID data (REQ0000029922), made by National Health 
Insurance Service. The authors alone are responsible for 
the content and writing of the paper.
AUTHORSHIP CONTRIBUTIONS
YP designed the study. MK and YP performed the 
mathematical and statistical analysis of the data. JKL 
performed additional statistical analysis for the revision 
of the manuscript and produced the data for the Tables. 
BK, HSL, and YP interpreted the results. BK and YP wrote 









All rights reserved - For personal use only 
No other use without premission
112
Kim B et al
Blood Transfus 2021; 19: 102-112  DOI 10.2450/2020.0050-20
The Authors declare no conf licts of interest. 
REFERENCES
1. Chapman JR. What are the key challenges we face in kidney 
transplantation today? Transplant Res 2013; 2: S1.
2. Department of Health & Human Services. Organ Procurement and 
Transplantation Network National Data Reoprt. Available at: https://
optn.transplant.hrsa.gov/data/view-data-reports/national-data/. 
Accessed on 07/01/2020.
3. Korean Network for Organ Sharing. Statistics of Organ Transplantation. 
Available at: https://www.konos.go.kr/konosis/index.jsp. Accessed on 
07/01/2020.
4. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the 
United States. PloS one 2014; 9: e84943.
5. Scornik JC, Bromberg JS, Norman DJ, et al. An update on the impact 
of pre-transplant transfusions and allosensitization on time to renal 
transplant and on allograft survival. BMC Nephrol 2013; 14: 217.
6. Mazzeffi M, Tanaka K, Galvagno S. Red Blood Cell Transfusion and surgical 
site infection after colon resection surgery: a cohort study. Anesth Analg 
2017; 125: 1316-21.
7. Brown CJ, Navarrete CV. Clinical relevance of the HLA system in blood 
transfusion. Vox Sang 2011; 101: 93-105.
8. Snyder EL. Prevention of HLA alloimmunization: role of leukocyte 
depletion and UV-B irradiation. Yale J Biol Med 1990; 63: 419-27.
9. Brubaker DB. Human posttransfusion graft-versus-host disease. Vox 
Sang 1983; 45: 401-20.
10. Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated 
blood components prepared by the British Committee for Standards 
in Haematology blood transfusion task force. Br J Haematol 2011; 
152: 35-51.
11. Asai T, Inaba S, Ohto H, et al. Guidelines for irradiation of blood and blood 
components to prevent post-transfusion graft-vs.-host disease in Japan. 
Transfus Med 2000; 10: 315-20.
12. Andersen CB, Ladefoged SD, Taaning E. Transfusion-associated 
graft-versus-graft and potential graft-versus-host disease in a renal 
allotransplanted patient. Hum Pathol 1992; 23: 831-4.
13. Sola MA, Espana A, Redondo P, et al. Transfusion-associated acute graft-
versus-host disease in a heart transplant recipient. Br J Dermatol 1995; 
132: 626-30.
14. Korea Centers for Disease Control and Prevention. National Transfusion 
Guideline. Available at: http://www.cdc.kr/board.es? mid=a40305010000&bid
=0019&act=view&list_no=138134&tag=&nPage=22. Accessed on 22/03/2020.
15. Cook DJ, Graver B, Terasaki PI. ABO incompatibility in cadaver donor 
kidney allografts. Transplant Proc 1987; 19: 4549-52.
16. Morath C, Zeier M, Dohler B, et al. ABO-incompatible kidney 
transplantation. Front Immunol 2017; 8: 234.
17. Koo TY, Yang J. Current progress in ABO-incompatible kidney 
transplantation. Kidney Res Clin Pract 2015; 34: 170-9.
18. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney 
transplantation using both A2 and non-A2 living donors. Transplantation 
2003; 75: 971-7.
19. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-
incompatible living kidney transplantation: a single-center experience. 
Transplantation 1998; 65: 224-8.
20. Knoll G. Trends in kidney transplantation over the past decade. Drugs 
2008; 68 (Suppl 1): 3-10.
21. Korean Network for Organ Sharing. Statistics Report on Organ 
Transplantation and Tissue Donation 2017. (Update on 2018.8.31.) 
Available at: https://www.konos.go.kr/konosis/index.jsp. Accessed on 
07/01/2020.
22. Kim Y, Chung B, Yang C. Current issues in ABO-incompatible kidney 
transplantation. J Korean Soc Transplant 2014; 28: 5.
23. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their 
outcome. Clin J Am Soc Nephrol 2011; 6: 922-36.
24. Badami KG. The immunocompromised patient and transfusion. Postgrad 
Med J 2001; 77: 230-4.
25. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors 
for rejection and graft loss after kidney transplantation. Am J Transplant 
2011; 11: 2132-43.
26. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-
onset diabetes on long-term transplant graft and patient survival. Clin J 
Am Soc Nephrol 2008; 3: 814-21.
27. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following 
renal transplantation. Am J Transplant 2006; 6: 357-63.
28. Hwang SD, Lee JH, Lee SW, et al. Efficacy and safety of induction therapy 
in kidney transplantation: a network meta-analysis. Transplant Proc 
2018; 50: 987-92.
29. Sheashaa HA, Hamdy AF, Bakr MA, et al. Long-term evaluation of single 
bolus high dose ATG induction therapy for prophylaxis of rejection in live 
donor kidney transplantation. Int Urol Nephrol 2008; 40: 515-20.
30. Tedesco Silva H Jr., Rosso Felipe C, Medina Pestana JO. Reviewing 15 
years of experience with sirolimus. Transplant Res 2015; 4: 6.
31. Wagner M, Earley AK, Webster AC, et al. Mycophenolic acid versus 
azathioprine as primary immunosuppression for kidney transplant 
recipients. Cochrane Database Syst Rev 2015: CD007746.
32. Gheorghian A, Schnitzler MA, Axelrod DA, et al. The implications of acute 
rejection and reduced allograft function on health care expenditures in 








All rights reserved - For personal use only 
No other use without premission
